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ABSTRACT
BACKGROUND: Haloperidol has been used as an effective antipsychotic for many years and
continues to be one of the first options in difficult patients who require parenteral therapy in
the acute phase. However, the depot form is less preferred in the treatment of patients with
non-adherence among these patients whose clinical stabilization has been achieved by using
parenteral haloperidol in the acute phase. Therefore, updating the information about the
side effects of the depot form of haloperidol, which is still an effective treatment option, will
be useful in reconsidering the position of this medicine among new and different options.
METHODS: A total of 54 schizophrenic patients with severe symptoms and poor adherence to
treatment who were hospitalized and treated with depot haloperidol following an acute
stabilization period were included in this study. First, the Structured Clinical Interview for
DSM-IV Axis I disorders (SCID-CV) was used to confirm the diagnosis, the Brief Psychiatric
Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the
Assessment of Negative Symptoms (SANS) to assess the clinical severity and Global
Assessment of Functioning (GAF) to assess the functionality. The Simpson-Angus Scale (SAS)
was used to assess extrapyramidal side effects. With the exception of Visit 0, plasma
haloperidol levels were measured at all visits. Also, measurements of waist circumference
and weight, plasma fasting blood glucose, triglyceride, HDL, iron, haemoglobin (Hgb),
prolactin (PRL) and HbA1c were also used for evaluation of the metabolic effects.
RESULTS: Significant improvements were observed in the BPRS, SANS, SAPS scores in the long-
term follow-up with the depot haloperidol treatment. While the dosage decreased over time,
the plasma levels remained changed, and symptom improvement was maintained. No signs
such as neuroleptic malignant syndrome or acute dystonia were observed and SAS scores
were within acceptable limits during the treatment (μ = 1.40 ± 2.55). There is no statistically
significant difference between measurements of the weight even there was a significant
difference between three of the waist circumference values (p = 0.987). The first
measurement of the waist circumference is statistically significantly higher than both the
mid-measurement and the final measurement, interestingly (p = 0.002). When fasting blood
glucose, triglyceride, HDL, iron, Hgb, PRL and HbA1c were measured at different times
throughout the study, only prolactin levels increased significantly over time with the use of
haloperidol (p < 0.001). At the end of a year, 50% of the patients participating in the study
still continued to use the haloperidol decanoate. This means also that half of the patients
had stopped to use haloperidol decanoate. However, only 18.5% of them (n = 5)
discontinued use of this drug because of extrapyramidal side effects.
CONCLUSION: Depot haloperidol remains an effective treatment option that improves treatment
compliance in challenging schizophrenia patients with severe symptoms. The long-term
metabolic and extrapyramidal side effect profile of the patients were generally within the safe
limits with the use of haloperidol depot. According to the obtained data, the depot haloperidol
continues to be a reliable treatment option in terms of adverse effects in the maintenance
treatment of schizophrenia patients with severe symptoms and poor adherence to treatment.
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Introduction
Schizophrenia is a disabling and chronic illness which
can cause severe difficulties in personal, social and
occupational functioning with a burden on patients,
their families, and community. Psychotic episodes,
partial or full remissions, relapses take part in the
long-term nature of schizophrenia. The symptoms of
disease begin at early puberty and show chronicity
and there may be a long duration of hospitalizations
and high costs due to the chronic relapses [1]. In
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addition, since the increased risk of violence, suicide
attempts and substance abuse during the period of
relapsewere observed, long-acting injectable antipsy-
chotics (LAIs) were produced in the 1960s to make bet-
ter the long-term treatment of schizophrenia. In a
recent cohort-study involving 29.823 individuals,
LAIs have been found to superior to oral antipsychotics
in terms of relapse prevention [2]. In another study,
LAIs have not only been found to be more effective
than oral antipsychotics for the prevention of relapses,
but also for the management of other problems such as
substance abuse and reduced quality of life [3]. San
et al. published that 1646 patients with schizo-
phrenia/schizoaffective disorder who are admitted to
acute care and the main reason for 58.6% of these
patients for hospital admission was non-adherence
[4]. In the other study non-adherence with antipsycho-
tic treatment is higher, with up to 75% of patients had
been non-adherent with antipsychotic medication at 2
years of post-hospital discharge. Although non-adher-
ence rates are between 50% and 75%, use of LAI is still
below the desired level in most of the countries.
Especially fear of serious adverse events are the reason
for this low level usage of LAI’s. There are many fears
related usage of LAIs like containing higher doses than
oral forms, possibility of combination with oral anti-
psychotics, loading dose procedures at beginning of
treatment and irreversible side effects after injection
[5]. Currently, there are two types of antipsychotics
which is named as the first-generation and second-gen-
eration LAIs in use. According to our classical knowl-
edge, some disadvantages and side effects exist for both
types of drug groups. While the first-generation LAIs
accused of extrapyramidal symptoms (EPSs) and tard-
ive dyskinesia, second-generation LAI’s hold respon-
sible with weight gain and metabolic syndrome so
contributing to the risk of type 2 diabetes and cardio-
vascular disease [6]. However, there are still conflicting
and missing information on the comparative tolerabil-
ity and cost-effectiveness of atypical and typicaldepot
formulations of antipsychotics, especially in a real-
world practice. The recent large trials and meta-ana-
lyses have also published that there is no effectiveness
or tolerability advantage between first-generation and
second-generation LAI’s [7,8]. In this article, we pre-
sent a one-year naturalistic follow-up study of patients
diagnosed with schizophrenia who were using haloper-
idol deconoate after the acute psychotic symptoms
controlled with parenteral and oral haloperidol.
Methods
Ethics approval
Approval for this observational follow-up study was
obtained from the Institutional Review Boards of Bakır-
köy Sadi Konuk Research and Training Hospital,
Istanbul (Prot. No. 2013/92) and the Head of Depart-
ment, Clinical DrugResearch, Agency for theMedicines
and Medical Devices, the Turkish Ministry of Health.
Selection and management of the patients
The study population consisted of schizophrenic
patients who were admitted to a major mental health
care facility (the Prof. Dr. Mazhar Osman Mental
Health and Neurological Disorders Hospital). Male
and female patients undergoing inpatient treatment in
segregated male and female (one male and one female)
patient wards for acute psychiatric disorders were
included. Patients with mental retardation, alcohol sub-
stance use for the last 3 months, relevant organic path-
ology were excluded. The departments in which the
patients were hospitalized function as psychiatric inten-
sive care units (PICU), which are specialized, high-
security wards with high staffing levels. The patients in
PICUs are acute and severely symptomatically challen-
ging with low treatment adherence and poor respon-
siveness to therapy. Rapid tranquilization is required
for most patients during the acute management phase.
A total of 54 consecutive patients responded well to
acute treatment with the first injection of haloperidol
were included in the study. The patients had the ana-
mnesis of noncompliance to treatment and inadequate
response to atypical antipsychotics and refusal of oral
treatment and expression of aggression and/or exci-
tation needs to chemical stabilization, so haloperidol
were preferred for their acute treatment. Depot halo-
peridol treatment was planned after acute treatment
with parenteral (i.m.) haloperidol because of the ana-
mnesis of low compliance to the treatment. All patients
or their legal representatives provided informed con-
sent to participate in the study. Despite individual
differences, the switch from parenteral to oral therapy
was accomplished within one week following the
improvement of symptoms and achievement of treat-
ment compliance. The patients also continued to
receive oral treatment for a week after parenteral treat-
ment. In this way, they were stabilized with haloperidol
treatment for a total of 14 days. When the clinical
stabilization was judged by the clinician, the treatment
with haloperidol decanoate was initiated with the gra-
dual tapering off the oral treatment. Additional treat-
ment with biperiden or lorazepam was allowed in
cases of side effects or psychomotor excitation.
Assessment parameters
(1) Assessment of clinical efficacy and functionality
for haloperidol decanoate
(2) Haloperidol plasma levels
(3) Extrapyramidal symptoms and metabolic side
effect profile
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(4) Long-term treatment adherence
Assessment of clinical efficacy and functionality
for haloperidol decanoate
The diagnoses were confirmed using the structured
clinical interview for DSM-IV axis I disorders (SCID-
CV) [9]. The treatment response was evaluated using
the Brief Psychiatric Rating Scale (BPRS) [10], the
Scale for the Assessment of Positive Symptoms
(SAPS) [11], and the Scale for the Assessment of Nega-
tive Symptoms (SANS) [12]. Functions were assessed
using the Global Assessment of Functioning (GAF)
[13]. These assessments were performed at the time
of admission, on the first day of haloperidol decanoate
administration, weekly for the following one-month
period, every two weeks in the second month, and
monthly thereafter. The assessment at the time of
admission was designated as Visit 0, and the day of
first haloperidol decanoate administration was desig-
nated as Visit 1. The following four visits (Visits 2 to 5)
were performed on a weekly basis. Then two visits
every two weeks (Visits 6 and 7) were conducted fol-
lowed by monthly visits (Visits 8 to 18). All patients
were followed-up for one year.
Haloperidol plasma levels
With the exception of Visit 0, plasma haloperidol levels
were measured at all visits. The plasma assays were per-
formed using a C18 chromatographic colon with a
mass-spectrometry reverse phase HPLC device (LC/MS;
Agilent 1200 Series).
Extrapyramidal and metabolic side effect profile:
The Simpson-Angus Scale (SAS) [14] was used for each
interview to assess extrapyramidal side effects. Waist
circumference and weight measurements were taken
at each visit; fasting blood glucose, triglyceride, HDL,
iron, haemoglobin (Hgb), prolactin (PRL) and
HbA1c measurements were performed at initial, 2, 5,
8 and 12 months to assess metabolic and haematologic
side effects.
Long-term compliance with therapy:
The interviews were conducted on the first day when
decanoate was made during hospitalization and then
once a week for the first month, once every 15 days
for the second month, then once a month. The assess-
ment made during the hospitalization was noted as
Interview 0 and the first interview when haloperidol
decanoate was administered was noted as Interview
1. The next 4 interviews (interview 2–5) were con-
ducted as a weekly follow-up. The interviews were con-
ducted every two weeks (interview 6–7) in next month
and then subsequent interviews were conducted
monthly [8–18]. In this way, one-year follow-up was
completed with the follow-up patients over time.
Since the study is a naturalistic observation study,
some of the patients continued on the last follow-up
interview at the 12th month of treatment, but some
of them left the treatment or removed from the fol-
low-up due to the change in the treatment protocol.
Some of them did not leave treatment but did not
come to the controls. It was learned that these patients
continued treatment at other centers by examining
pharmacy information system and hospital records.
These patients were evaluated as patients who contin-
ued haloperidol decanoate in terms of treatment com-
pliance. However, since the data of these patients were
incomplete because they were removed from the fol-
low-up, the efficacy monitoring parameters of the
patients who were remained in 12 months of follow-
up and who came to regular controls were evaluated.
Statistical analyses
The SPSS 24 forMac software programwas used to ana-
lyse the study data.Descriptive statistics (i.e.mean, stan-
dard deviation, frequency) were used to assess the study
results. The MANOVA was used with repeated
measures of more than two time-points in which the
parametric assumptions were met for the quantitative
data. The post-hoc Bonferroni test was used to identify
the causes of differences in the results. Friedman’s test
was used in repeated measures with more than two rep-
etitions in which parametric assumptions were not met.
The cause of the difference was identified using theWil-
coxon sign test. Spearman’s Rho correlation test was
used to evaluate the associations between variables in
which parametric assumptions could not be met. The
levels of significance were set at p < 0.016 and p < 0.007
with the Bonferroni correction.
To determine the changes in BPRS, SANS, SAPS
and GAF over time, the non-parametric Friedman’s
test was used instead of a one-way ANOVA for the
parametric repeated measures because the assumptions
of normal and global distribution were not met. The
Bonferroni correction was applied because multiple
scales were utilized. A p value of less than 0.01 was con-
sidered significant.
In our study, the difference between baseline, mid-
study, and one-year assessment time-points was exam-
ined, mainly for two reasons. Firstly, when a statistically
significant difference is identified in time-dependent
variables, a total of 153 post-hoc comparisons were
required to determine the parameter responsible for
the difference. Therefore, the Bonferroni correction
performed in this case would be too conservative, sig-
nificantly elevating the type 2 error risk. Secondly,
the interpretation of the differences detected between
multiple-measurements would be too complicated
and confound the significance assessments.
A third measurement, that is, the mid-study
measurement, was used not only because it coincided
with the middle portion of the study but also because
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a relative plateau was reached after a strong trend
toward that point.
Results
A total of 41 female and 13 male schizophrenic patients
between 25 and 75 years of age (mean 42.30 ± 10.22
years) were included. The patient characteristics are
shown in Table 1.
Baseline (Visit 0): the score recorded on the day of
first haloperidol dose.
Efficacy
Table 2 presents the comparison of the BPRS, SANS,
SAPS, SAS, and GAF scores during one year in the
patients who participated in the study.
The baseline BPRS scores were significantly higher
compared to those in the mid-study (Z = –4.346,
p < 0.001) and at the end of the study (Z = –3.409,
p = 0.001) scores. The mid-study BPRS scores
were significantly higher compared to the scores at
the end of the study (Z = –2.805, p = 0.005) (Figure 1).
The baseline SANS scores were significantly higher
compared to those in the mid-study (Z = –3.603,
p < 0.001) and at the end of the study (Z = –3.411,
p = 0.001). There were no significant differences
between the mid-study and the end-study measure-
ments (p > 0.016) (Figure 2).
The baseline SAPS were significantly higher com-
pared those in the mid-study (Z = –3.867, p < 0.001)
and at the endof the study (Z = –3.301, p = 0.001).
There were no significant differences between the
mid-study and the end-study measurements
(p > 0.016) (Figure 3).
The baseline GAF scores were significantly lower
compared to those in the mid-study (Z = –4.083,
p < 0.001) and at the end of the study (Z = –3.438,
p = 0.001). There were no significant differences
between the mid-study and the end-study measure-
ments (p > 0.016) (Figure 4).
Haloperidol dose and plasma levels
The changes in the haloperidol dose and plasma levels
from the study baseline, at mid-study, and at one-year
in the subjects who completed the follow-up period
were examined (Figure 5). Because the assumptions
of normal and global distributions were not met,
non-parametric Friedman’s test was used instead of
the one-way ANOVA for the parametric repeated
measures test. The results showed that the mean halo-
peridol dose at the end of the study was statistically sig-
nificantly lower than both the first dose (Z = –2.982,
p = 0.003) and the mid-study dose (Z = –2.591,
p = 0.010). Similarly, the mean haloperidol dose
received at mid-study was significantly lower than the
baseline dose (Z = –2.640, p = 0.008). However, the
alterations in plasma levels were not statistically signifi-
cant. Table 3 shows the haloperidol doses received by
the patients and their plasma levels.
Table 1. Distribution of clinical characteristics and scale scores
of the patients participating in the study.
N:54 Min–Max Mean + SD (Median)
Age 25–75 42.30 ± 10.22(41)
Education time 0–15 5.93 ± 3.17(5)
Disease Duration (years) 0–33 14.15 ± 8.51(13)
Hospitalization numbers 0–50 6.24 ± 9.78(3)
BPRS Baseline Score 6–62 34.54 ± 13.57 (36)
SANS Total Baseline Score 0–56 10.74 ± 7.66(10)
SAPS Total Baseline Score 1–18 7.33 ± 3.99(7)
SAS Baseline Score 0–13 1.40 ± 2.55(0)
GAF Baseline Score 15–75 33.07 ± 11.35(35)
Table 2. Comparison of baseline and final scores in patients completing the study.
N:17 First score Mid-study score Final score
Mean ± SD (Median) Mean ± SD (Median) Mean ± SD (Median) χ2(2) p
BPRS 36.47 ± 12.61 (38) 6.13 ± 7.49 (4) 0.73 ± 1.71 (0) 28.182 <0.001
SANS 12.80 ± 12.73 (11) 5.20 ± 11.48 (0) 0.53 ± 1.13 (0) 26.941 <0.001
SAPS 8.40 ± 3.96 (8) 0.93 ± 1.53 (0) 0.60 ± 2.06 (0) 26.000 <0.001
GAF 32.33 ± 12.66 (30) 60.73 ± 15.12 (60) 68.67 ± 10.60 (70) 25.107 <0.001
Figure 1. Change in BPRS scores over time.
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Extrapyramidal symptoms and metabolic side
effect profile
To investigate extrapyramidal side effects, the
relationship between SAS scores and haloperidol
doses was first investigated. According to this; there
was a statistically significant correlation between the
initialdose of haloperidol and SAS scores in the posi-
tive direction (p < 0.05), but there was no statistically
significant correlation between the dose of haloperi-
dole decanoate and SAS scores in the middle and
final assessments (p > 0.05). The relationship between
haloperidol dose and SAS side effect scale scores of
the patients who completed the study is given in
Table 3 and the change in SAS scale scores over
time is given in Figure 6.
The changes in metabolic measurements (fasting
blood glucose, triglyceride, HDL, iron, Hgb, PRL and
HbA1c) of patients who completed the study over
time were compared. As the metabolic properties
were examined with more than one variable, Bonfer-
roni correction was used to determine whether there
was any difference between the measurements. There-
fore, univariate analysis results were evaluated at p =
0.007 level. Non-parametric Friedman Test analysis
was used because parametric assumptions such as nor-
mal distribution and sphericity were not met in the
variable groups. According to this; there is a statisti-
cally significant difference between measurements of
PRL variable over time (p < 0.007) (Figure 7).
The Wilcoxon Sign Rank Test was used to determine
the source of the difference, the results of the binary
Figure 3. Change in SAPS scores over time.
Figure 2. Change in SANS scores over time.
Figure 4. Change in GAF scores over time.
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comparisons were assessed by Bonferroni correction and
the level of significance was determined as p < 0.005.
According to the binary comparison results, the first
PRL measurement was statistically significantly lower
than the third (Z = –3.411, p = 0.001, effect size dcohen=
2.95, large effect size), fourth (Z = –2.831, p = 0.0046,
effect size dcohen= 1.89, large effect size) and fifth
(Z = –2.985, p = 0.003, effect size dcohen = 2.09, large
effect size). There was no statistically significant differ-
ence between the other measures (p > 0.005) (Table 4).
Measurements of weight and waist circumference
were also used to evaluate the metabolic side effects
of haloperidol. Weight and waist circumference
measurements of the follow-up patients were evaluated
with MANOVA for repeated measurements. Both
weight and waist circumference measurements seem
to meet the assumptions of the normal distribution
(Shapiro–Wilk p > 0.05) and sphericity (For weight;
χ2 (2) = 2.901, p = 0.234, for waist circumference
χ2(2) = 5.398, p = 0.067).
The MANOVA multivariate test results for recur-
rent measurements were statistically significant
(Wilk’s λ = 0.618, F(4, 54) = 3.679, p = 0.010, Partial
η2 = 0.21) and univariate results were examined to
determine if there is a significant difference between
the measurements for which variable(s). According to
this, there was no statistically significant difference
between measurements in weight variable, but there
was a significant difference in waist circumference
(p < 0.01, Partial η2 = 0.35, large effect size). For the
determination of the source of the difference, Bonferroni
correctedbinary comparison results havebeen examined.
Accordingly, the first measurement of waist circum-
ference was statistically significant high (p < 0.016)
than both the mid- and final measurements. There
was no statistically significant difference between the
middle measurement and final measurement for
waist circumference (p > 0.016) (Table 5).
Compliance with treatment
In the study, the proportion of patients to continue treat-
ment for 1 year were evaluated and 50% of the patients
(n:27) continued to use haloperidol decanoate when the
whole groupwas evaluated, 14.8% (n:8) switched to anse-
cond-generation antipsychotics (SGAs), 7.4% (n:4) used
a mood stabilizer with another SGA, 7.4% (n:4) switched
to another depot antipsychotic. 20.4% of the patients
(n:11) had completely left the treatment. As a result,
50% of the patients were still on haloperidol treatment
and 79.6% of the patients were still on treatment at the
end of 1 year. When the causes of treatment discontinu-
ation were evaluated, it was determined that treatment
Table 3. The Relationship between haloperidol dose and SAS
side effect scale scores of patients completing the study.
** SAS initial SAS middle SAS final
Haloperidol Initial dose (n = 53) –0.339*
Haloperidol Middle dose (n = 25) –0.061
Haloperidol Final dose (n = 17) 0.060
Figure 5. Change in plasma haloperidol levels over time.
Figure 6. Changes in SAS scale scores over time.
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was changed with the recommendation of the following
doctor due to a change in the initial diagnosis or due to
side effects in 37% of patients, 33.3% of the patients
had no social support to provide access to treatment,
29.6% of patients discontinued treatment with their
request. The side effects were reported only 5 of the
patientsas a cause by their doctor (Figure 8).
Discussion
With regard to efficacy, haloperidol decanoate showed a
treatment effect as early as the first week of treatment. Of
particular note in terms of efficacy was the continued
improvement in BPRS, SANS, and SAPS scores in the
patients who initially responded to oral haloperidol and
who were considered suitable for the depot formulation.
The results showed that the reduction in BPRS scores
continued to decline until the end of the one-year period.
An important aspect of this study is that it was based
on a one-year follow-up in a real-life treatment setting.
The dosages were adjusted according to the clinical
needs of the patients, who were followed-up during the
natural course of their real-life conditions. Thus, the
reduction in SAPS, SANS, and BPRS scores and
the improvement in functions are clinically significant.
The improvement in patient function is an indication
that not only were the patients tranquilized but also
they regained some functionality in their daily living
activities.
We believe that the inclusion of hard-to-treat
schizophrenic patients is an important feature of the
current study. Rapid tranquilization was required
because of the agitation and excitation in this challen-
ging group of patients with severe symptomatology.
The treatment of these patients with haloperidol
resulted in the presented findings. In a previous
meta-analysis comparing the efficacy of antipsychotics
in patients with inadequate response to treatment or
with treatment resistance, second-generation antipsy-
chotic agents, such as olanzapine and risperidone,
were found to be effective in addition to clozapine [15].
Although clozapine is an effective therapeutic
option in treatment-resistant schizophrenia, only 40%
of patients benefit from this agent. The search for a
novel drug continues because clozapine is associated
with several undesirable effects, including agranulocy-
tosis, myocarditis, thromboembolism, ileus, and pneu-
monia [16,17]. Furthermore, the presence of
intramuscular formulations of haloperidol, which is
suitable for patients resistant to treatment during
acute episodes, represents an important advantage
over clozapine and other oral antipsychotics because
it provides rapid tranquilization. Regarding mainten-
ance therapy, although other second-generation anti-
psychotics are a therapeutic option, the results of the
present study indicate that haloperidol decanoate
may also be considered a viable treatment in hard-to-
treat patients.
In our patients, the plasma haloperidol decanoate
levels remained above 4 μg/L at both 6- and 12-
month assessments. This level is considered to rep-
resent a threshold for both clinical efficacy and reduced
relapse risk [18,19]. It has been reported that signifi-
cantly lower doses of haloperidol decanoate may be
administered in the third or fourth month of treatment
compared to the initial oral doses. Similarly, the halo-
peridol doses given to the patients in the present
study declined over time, and clinical stability was
maintained at these lower dose levels. Steady-state
plasma haloperidol levels were reported to occur after
the second month of treatment with haloperidol decan-
oate [20], and clinical stability was maintained even
after plasma concentrations were reduced in the
remaining course of the treatment [21]. The results of
our analysis showed that the reduced doses of depot
haloperidol administered to the patients were not
accompanied by similar levels of decline in plasma
haloperidol levels, which suggests that the same plasma
levels could be achieved using gradually reduced doses.
The “flip-flop” phenomenon has been reported in the
pharmacokinetics of haloperidol, showing an absorp-
tion half-life longer than an elimination half-life [18].
This finding implies that lower doses may be needed
over longer terms. Compared with oral haloperidol,
lower haloperidol plasma levels have been detected
during treatment with haloperidol decaonate. This
effect may be related to the pharmacokinetic differ-
ences between the two formulations as well as the
Figure 7. Changes in prolactin levels over time.
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absence of several parameters in parenteral drug
administration, including gastrointestinal absorption
and hepatic first-pass metabolism [20]. In this regard,
our results are consistent with previous reports [19].
The results of our study showed that a loading dose
of haloperidol decanoate may be safely and effectively
administered to acutely ill patients, which is in line
with the findings of previous studies in which loading
doses of this agent were used [19–23]. Among the pre-
vious studies that also examined plasma haloperidol
decanoate levels, the current study is distinguished by
the long duration of the follow-up.
Extrapyramidal symptoms (EPS) which contains
acute dystonia, akathisia, parkinsonism and tardive
dyskinesia can be observed in two phases. While
early-onset EPS like acute dystonia and akathisia devel-
ops at the beginning of treatment with antipsychotics
or when the dose is increased, the late-onset EPS like
tardive dyskinesia (TD) usually occurs on future
stage of treatment. Acute EPS usually resolve with
dose reduction of the antipsychotic or require anticho-
linergic treatment [24]. It has been reported that
neurologic side effects are related to the dose of anti-
psychotic drugs [25]. In previous studies, it was also
published that when the haloperidol dose have been
increased in the treatment, the extrapyramidal side
effects of antipsychotic also increase [26]. In addition,
it has been reported that haloperidol reaches steady-
state plasma level after second application of haloperi-
dol decanoate [20] and that patients remain clinically
stable even if plasma concentrations decrease in the
later stages [21]. In the light of this information, we
also decreased the initiating dose of haloperidol in
order to avoid side effects. In this way, while there
was a statistically significant correlation between the
beginning initial dose of haloperidol and EPS scores
in the positive direction, no statistically significant
relationship was found between the middle and final
dose of the haloperidol treatment and EPS scores.
When our patients were examined for side effects
also, it wasn’t any sign such as neuroleptic malignant
syndrome or acute dystonia and SAS scores were at
acceptable limits during the treatment although five
of patients dropped out from the study because of
side effect. While acute dystonia is common with halo-
peridol, it was also published that 7.2% of the patients
who had used long-acting risperidone had an acute
dystonia [27]. Also, after initiation of aripiprazole or
ziprasidone treatment, acute dystonia could be
observed as a side effect [28,29]. In the Clinical Anti-
psychotic Trials of Intervention Effectiveness
(CATIE) study, which compared the first-generation
antipsychotic (FGA) (perphenazine) with atypical anti-
psychotics (olanzapine, quetiapine, risperidone, zipra-
sidone) in schizophrenia groups, no significant
differences across the groups in the incidence of EPS,
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discontinued treatment due to extrapyramidal adverse
effects [30]. It wasalso reported that akathisia rates
similar between FGAs and second-generation antipsy-
chotics (SGAs) [31]. The Cost Utility of the Latest
Antipsychotics in Schizophrenia Study Band 1
(CUtLASS-1) is a randomized controlled trial (RCT)
that tested the differences of the clinical and cost-effec-
tiveness between FGAs and SGAs. In this study, FGAs
have a trend towards better outcomes and lower costs.
There were no significant differences in rates of objec-
tively assessed extrapyramidal side effects between the
SGA and FGA patients [7]. There are also some studies
that show the opposite results in the literature. Lam-
mers et al. published that although there was no appar-
ent difference in treatment discontinuation or
hospitalization between second-generation antipsycho-
tic long-acting injectable (SGA-LAI) and first-gener-
ation depot antipsychotics treated patients. EPS
which were more common in first-generation depot
antipsychotics treated patients [32]. In the previous
study, paliperidone palmitat and haloperidol deconate
were compared and haloperidol deconate was shown to
have a higher risk of akathisia, although the long-term
effects of paliperidone were not superior [33]. Zhao
et al. found that fluphenazine decanoate, haloperidol,
haloperidol decanoate and trifluoperazine produced
more extrapyramidal adverse effects than olanzapine
or quetiapine. Again when the patient used paliperi-
done palmitate and risperidone microspheres, co-
medication against extrapyramidal symptoms was
less frequently used compared to with haloperidol
decanoate [34].
Although many controversial studies have been
published about efficacy and side effects, SGAs have
been increasingly used in the treatment of schizo-
phrenia in preference to FGAs recently [35]. It was
thought that SGAs are promoted as offering several
therapeutic advantages when compared with the
FGAs like enhanced efficacy for negative symptoms,
low extrapyramidal side effects etc. [36]. However, it
is now believed that all SGAs, except clozapine, have
capacity lead to EPS and the last studies have also
shown that there is no advantage of SGAs regarding
tolerability and effectiveness compared with FGAs.
There are also a lot of disadvantages to use of SGA’s
compared with FGAs for metabolic syndrome [6]
include weight gain, obesity, glucose intolerance, insu-
lin resistance, dyslipidemia and hypertension. In our
study there is also no statistically significant difference
between measurements of the weight in our natural fol-
low-up study throughout 12 months, however, there
was a significant difference between three of the waist
circumference values. The first measurement of the
waist circumference is statistically significantly higher
than both the mid-measurement and the final
measurement interestingly. Since the treatment of
schizophrenic patients with atypical antipsychotics is
very common nowadays, these patients may be treated
with atypical antipsychotics before haloperidol decano-
ate treatment. 62 schizophrenic patients who were trea-
ted with typical (haloperidol) and atypical (clozapine,
risperidone, olanzapine, quetiapine, aripiprazole) anti-
psychotics were observed over 20 years by Francesco
&Cervone. They point out that at the endpoint of the
period of observation [20 years) the patients with halo-
peridol reported satisfactory and a better glycemic and
lipidic profiles than SGA’s [37]. It was reported also no
change in prevalance of metabolic syndrome (MetS) in
FGA group (perphenazine) in CATIE study at follow-
up for three months, however, an increase in preva-
lance of MetS was seen in SGA group (olanzapine)
[38]. In Meteor study also which was consist of 2270
adults with schizophrenia, significantly higher frequen-
cies of dysglycaemia, low HDL cholesterol and meta-
bolic syndrome were observed in patients taking SGAs
considered to carry high metabolic risk [39]. De Hert
et al. had reported that the odds of developing MetS
were 3-fold in patients started on SGAs compared to
FGAs in MetS naive first-episode patients with schizo-
phrenia. Approximately 1 out of 3 first-episode patients
met criteria of MetS after three years of begining of
SGAs [40]. It was explained by Lindenmayer et al. that
a higher weight gain, elevated postload glucose and
cholesterol level in SGA group (clozapine and olanza-
pine), compared with FGA (haloperidol) group, also
had been recognized that higher prevalence of diabetes
in clozapine-treated patients [41]. Although it is not
appropriate to compare second-generation antipsycho-
tics with haloperidol all together, these studies are also
important to give an idea about differences between
Table 5. Comparison of weight and waist circumference measurements of follow-up patients RepeatedMeasures MANOVA.
N:17 Initial measurement Middle measurement Final measurement
Mean ± SD (Median) Mean ± SD (Median) Mean ± SD (Median) F(2, 28) p Partial η2
Weight 69.20 ± 15.29 (65) 69.20 ± 14.60 (67) 69.53 ± 12.90 (67) 0.013 0.987 0.001
Waist circumference 94.13 ± 16.42 (99) 86.07 ± 11.99 (83) 84.53 ± 14.72 (82) 7.588 0.002 0.352
Figure 8. Percentage of reasons why patients discontinued
haloperidol decanoate treatment.
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SGAs and FGAs. When we search if there is any study
where SGA antipsychotics compare with haloperidole
separately, the current meta-analysis is consist of
fifteen antipsychotics (only haloperidol was used as a
member of FGA medication) and mutual comparisons
between antipsychotics showed that haloperidol had
the least effect over weight gain [42]. Fasting blood glu-
cose, triglyceride, HDL, iron, Hb, PRL and HbA1c were
measured at baseline 2, 5, 8 and 12th month in our
study. Among all these measures, only prolactin levels
increased significantly over timewith the use of haloper-
idol. There was no significant statistical change in other
metabolic parameters. Currently, it is a generally
accepted approach to categorize antipsychotics accord-
ing to their effects on prolactin levels as prolactin-rais-
ing and -sparing antipsychotics. Among SGA’s,
risperidone, paliperidone, amisulpride, and sulpiride
are the ones that lead to an increase in the prolactin
level with the highest rate. FGA and zotepine lead to a
marked increase in prolactin levels, whereas clozapine,
olanzapine, quetiapine, ziprasidone, sertindol, and ase-
napine lead to slight or transient increases [43]. In the
literature, there are studies that investigate the relation
between haloperidol use and prolactin level and obtain
different results. David et al. examined the comparative
effects on PRL of olanzapine, risperidone, and haloper-
idol in multicenter, double-blind, randomized clinical
trials. They published that PRL is elevated moderately
by olanzapine, intermediately by haloperidol and
strongly by risperidone [44]. In contrast another study
where prolactin levels had been measured in 110
patients with medication-naive and first-episode psy-
chosis, olanzapine and haloperidol treatments didn’t
significantly affect serum prolactin levels at long term
although elevated prolactin levels persisted in most
patients were treated with risperidone after a year
[45]. Although the results of these comparisons are
expected to come against risperidone, these results are
important to see position of haloperidol among the
other antipsychotics. We know that risperidon consta
can be administered every twoweeks so we should com-
pare the antipsychotics that must be applied every
month like haloperidol. When we look at the studies,
Mc Evoy et al. reported that serum prolactin concen-
trations were significantly higher with once monthly
formulations of paliperidone palmitate than with halo-
peridol decanoate in both men and women (p < 0.001);
however, there were no significant differences in sexual
dysfunction or galactorrhea [33].
Although duration of the study was relatively short
to assess some side effects like tardive dyskinesia none
of the patients had left from our study because of tard-
ive dyskinesia. Again when paliperidone palmitat and
haloperidol deconate were compared by McEvoy
et al., it was found that treatment discontinuations
due to tardive dyskinesia according to clinician judg-
ment were as follows 2.7% on haloperidol deconate
compared to 0.7% on paliperidone palmitat [33]. In
the study of Novick et al., the patients treated with typi-
cal antipsychotic agents (oral and depot) and risperi-
done had a higher risk of developing EPS and TD
than the patients treated with olanzapine [46]. In our
study patients were followed with haloperidol decano-
ate and since low dosage procedures were applied, we
may not have observed tardive dyskinesia-related sep-
aration from our study.
Marcus et al published that both first-generation
antipsychotic long-acting injectable (FGA-LAI) and
second-generation antipsychotic long-acting injectable
(SGA-LAI) have benefits in terms of adherence and
re-hospitalizations among currently hospitalized, non-
adherent patients with schizophrenia [47]. Some studies
have shown that a higher rate of adherence among
patients receiving SGA’s compared with those receiving
FGA’s [48]. In contrast, some studies published that
there was no apparent difference in treatment discon-
tinuation between SGA’s and FGA’s treated patients.
Again Nielsen et al. published that SGA-LAIs not
superior to FGA-LAIs regarding time to psychiatric
hospitalization, all-cause discontinuation, and duration
of hospitalization [49]. In our study when adherence to
treatment was observed throughout a year, it was seen
that half of the patients continued to use the depot halo-
peridol, the rate of continuity of the depot haloperidol
was 50% and the rate of continuity any treatment was
79.6%. This is a high continuity rate for patients with
schizophrenia since the CATIE study showed that
74% of patients had discontinued medication within
18 months due to insufficient efficacy, intolerable side
effects etc. [30]. All of these results may suggest that
haloperidol deconoate choice is positively associated
with adherence to treatment with appropriate follow-
up and treatment planning. It was also suggested that
antipsychotic side effects are associatedwith lower levels
of adherence. Hudson et al. found that approximately
35% of patients, Loffler et al. also published that 50%
of patients had side effects as a reason for non-adher-
ence [50,51]. Although EPS/agitation-related side
effects were the most strongly associated with non-
adherence in previous studies, only 5 of the patients
(18.5%) terminated the treatment due to the cause of
extrapyramidal side effects in our study.
When the causes of non-adherence were evaluated in
our study, it was learned that 37% of the patients had
changed the treatment with his/her doctor’s effect;
33.3% of the patients discontinued treatment because
of inadequate social support to provide access to treat-
ment; and 29.6% of the patients left treatment with
their desire. In one study consist of 100 patients starting
long acting risperidone, 51% discontinued during the
first 6 months. The reasons for discontinuation were
that the ineffective medication (47%), refused (35%),
or not tolerated by the patient (18%) [52]. Although
this study has been done with the patients who were
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treated with long acting atypical antipsychotic, the
results were similar to our haloperidol decanoate study.
The weaknesses of this study were lack of control
group, including the sample consisted of a small num-
ber of treatment-resistant patients who is likely to have
an adherence problem and since the study does not
consist of first-episode psychotic patients, the possi-
bility of earlier use of a wide variety of oral form anti-
psychotics. In addition, strengths of this study are the
one-year naturalistic observation study, inclusion of
patients in consecutive way, questioning whether or
not they are currently using treatment by reaching
the patient who is leaving the follow-up and also check-
ing whether or not patients receive drugs from phar-
macies via the computer system if satisfactory
information cannot be obtained, standardization of vis-
its and treatments to be the same for each patient.
Conclusion
It is important that this study is a natural follow-up study
which demonstrated that the haloperidol deconoate is
still unique as an effective and tolerable treatment option
in schizophrenia patients with severe and non-adherence
to pharmaceutical treatment. The availability of effective
treatment options for patients with clinical severity and
non-adherence to drugs is facilitating the treatment pro-
cess for both the patients and physicians in real life.
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